Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Oral Bioavailability of GLPG0555 in Different Solid Formulations

This study has been completed.
Information provided by:
Galapagos NV Identifier:
First received: January 14, 2011
Last updated: March 23, 2011
Last verified: March 2011
The purpose of the study is to compare the pharmacokinetics of a solid capsule formulation of GLPG0555 with a nanosuspension, and to assess safety and tolerability of a single dose of GLPG0555.

Condition Intervention Phase
Drug: GLPG0555 solid dispersion
Drug: GLPG0555 nanosuspension
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Randomized, Open Label, 3-way Crossover Study to Compare the Oral Bioavailability of GLPG0555 After Single-dose Intake in Healthy Subjects as a Solid Dispersion Formulation, With and Without Food, Relative to a Nanosuspension Formulation

Further study details as provided by Galapagos NV:

Primary Outcome Measures:
  • Bioavailability of solid formulation [ Time Frame: 72 hrs ]

Secondary Outcome Measures:
  • Safety and tolerability of single doses of GLPG0555 [ Time Frame: up to 10 days postdose ]

Enrollment: 12
Study Start Date: January 2011
Study Completion Date: March 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GLPG0555 solid dispersion, fasting
50 mg as solid dispersion capsule, in fasting condition
Drug: GLPG0555 solid dispersion
solid dispersion capsules, 50 mg, single dose
Experimental: GLPG0555 solid dispersion, fed
50 mg as solid dispersion capsule, after breakfast
Drug: GLPG0555 solid dispersion
solid dispersion capsules, 50 mg, single dose
Experimental: GLPG0555 nanosuspension, fed
50 mg as nanosuspension, given after breakfast
Drug: GLPG0555 nanosuspension
Nanosuspension, 50 mg, single dose


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy male
  • BMI between 18-30 kg/m², inclusive.

Exclusion Criteria:

  • significantly abnormal platelet function or coagulopathy
  • smoking
  • drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01278095

SGS Stuivenberg
Antwerp, Belgium, 2060
Sponsors and Collaborators
Galapagos NV
Study Director: Gerben van 't Klooster, PhD Galapagos NV
Principal Investigator: Jos Leempoels, MD SGS Stuivenberg
  More Information

Responsible Party: Senior Vice President Development, Galapagos Identifier: NCT01278095     History of Changes
Other Study ID Numbers: GLPG0555-CL-103
2010-022457-42 ( EudraCT Number )
Study First Received: January 14, 2011
Last Updated: March 23, 2011

Keywords provided by Galapagos NV:
Pharmacokinetics processed this record on April 28, 2017